On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics.
作者信息
Gopal Anand D, Wallach Joshua D, Shah Saloni A, Regillo Carl, Ross Joseph S
机构信息
Wills Eye Hospital, Philadelphia, Pennsylvania.
Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut.
出版信息
Ophthalmology. 2021 Feb;128(2):332-334. doi: 10.1016/j.ophtha.2020.07.028. Epub 2020 Jul 16.
Abstract
摘要
相似文献
1
On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics.
Ophthalmology. 2021 Feb;128(2):332-334. doi: 10.1016/j.ophtha.2020.07.028. Epub 2020 Jul 16.
2
Eyes on new product development.
J Ocul Pharmacol Ther. 2012 Dec;28(6):557-8. doi: 10.1089/jop.2012.0229.
3
Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Johns Hopkins Med Lett Health After 50. 2011 Jun;23(4):7.
4
The accelerated drug approval.
Ocul Surf. 2010 Oct;8(4):205-7. doi: 10.1016/s1542-0124(12)70235-5.
5
United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
Fordham Law Rev. 2018 Apr;86(5):2595-623.
6
Eyes on new product development.
J Ocul Pharmacol Ther. 2013 Sep;29(7):611. doi: 10.1089/jop.2013.1509.
7
Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
Clin Pharmacol Ther. 2020 Nov;108(5):985-994. doi: 10.1002/cpt.1757. Epub 2020 Jan 25.
8
Pharmaceuticals and medical devices: FDA oversight.
Issue Brief Health Policy Track Serv. 2012 Jan 3:1-86.
9
Unapproved Ophthalmic Drugs.
Ocul Surf. 2016 Apr;14(2):317-20. doi: 10.1016/j.jtos.2016.03.001.
10
Off-label, not off-limits: the FDA needs to create a safe harbor for off-label drug use.
Mo Med. 2013 Mar-Apr;110(2):106-9.
引用本文的文献
1
COVID-19 impact on research and publication ethics.
Med Hypothesis Discov Innov Ophthalmol. 2021 May 31;10(1):1-4. doi: 10.51329/mehdiophthal1414. eCollection 2021 Spring.
2
The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.
Int J Environ Res Public Health. 2022 Feb 17;19(4):2303. doi: 10.3390/ijerph19042303.
3
Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy.
Clin Ophthalmol. 2021 Dec 18;15:4731-4738. doi: 10.2147/OPTH.S339393. eCollection 2021.
本文引用的文献
1
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410.
2
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031.
3
Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.
BMJ Open. 2017 Dec 21;7(12):e018587. doi: 10.1136/bmjopen-2017-018587.
4
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population.
JAMA Intern Med. 2016 Jan;176(1):55-63. doi: 10.1001/jamainternmed.2015.6058.
5
U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1094-100. doi: 10.1002/pds.1825.
6
Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents.
JAMA. 2007 May 9;297(18):2001-9. doi: 10.1001/jama.297.18.2001.
Zotero 插件